Summit Therapeutics (SMMT) News Today $19.10 +0.21 (+1.11%) Closing price 09/22/2025 04:00 PM EasternExtended Trading$19.38 +0.27 (+1.44%) As of 06:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SMMT Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Wealth Management Partners LLC Cuts Stock Position in Summit Therapeutics PLC $SMMTSeptember 21 at 6:26 AM | marketbeat.comVoya Investment Management LLC Lowers Stock Position in Summit Therapeutics PLC $SMMTSeptember 20 at 3:20 AM | marketbeat.comJim Cramer on Summit Therapeutics: “We’re Going to Have to Move On”September 19, 2025 | msn.comBarclays Upgrades Summit Therapeutics (NASDAQ:SMMT) to "Strong Sell"September 19, 2025 | marketbeat.comRockland Trust Co. Buys Shares of 400,000 Summit Therapeutics PLC $SMMTSeptember 19, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTSeptember 18, 2025 | prnewswire.comSummit Therapeutics (NASDAQ:SMMT) Coverage Initiated at BarclaysSeptember 18, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Now Covered by Analysts at BarclaysSeptember 18, 2025 | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Receives Buy Rating from HC WainwrightSeptember 17, 2025 | marketbeat.comFocus Partners Wealth Boosts Stake in Summit Therapeutics PLC $SMMTSeptember 17, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Summit Therapeutics (NASDAQ:SMMT)September 17, 2025 | americanbankingnews.comSummit Therapeutics Inc. Investigated by the Portnoy Law FirmSeptember 16, 2025 | globenewswire.comInsiders Are Aggressively Buying These 5 StocksSeptember 16, 2025 | 247wallst.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Up Following Insider Buying ActivitySeptember 14, 2025 | marketbeat.comSummit Therapeutics PLC (NASDAQ:SMMT) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 14, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) CEO Robert Duggan Acquires 333,394 SharesSeptember 13, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) CEO Mahkam Zanganeh Buys 333,394 SharesSeptember 13, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTSeptember 13, 2025 | prnewswire.comSiren L.L.C. Takes $13.41 Million Position in Summit Therapeutics PLC $SMMTSeptember 13, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Up After Insider Buying ActivitySeptember 13, 2025 | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Stock Price Down 6.2% - Should You Sell?September 12, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) CEO Robert Duggan Purchases 5,000 SharesSeptember 12, 2025 | insidertrades.comSummit Therapeutics PLC (NASDAQ:SMMT) Receives Average Rating of "Moderate Buy" from AnalystsSeptember 12, 2025 | americanbankingnews.comSummit Therapeutics (SMMT) Is Down 21.0% After Mixed HARMONi Trial Data Raises Global Approval QuestionsSeptember 10, 2025 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTSeptember 10, 2025 | globenewswire.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Down - Here's What HappenedSeptember 10, 2025 | marketbeat.comSummit Therapeutics (NASDAQ:SMMT) Receives "Overweight" Rating from Cantor FitzgeraldSeptember 10, 2025 | marketbeat.comSummit Therapeutics' (SMMT) Buy Rating Reiterated at HC WainwrightSeptember 10, 2025 | marketbeat.comCORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law FirmSeptember 9, 2025 | globenewswire.comSummit Therapeutics Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 24, 2025 Deadline to file Lead Plaintiff Motion.September 9, 2025 | globenewswire.comPolar Asset Management Partners Inc. Trims Holdings in Summit Therapeutics PLC $SMMTSeptember 9, 2025 | marketbeat.com538,000 Shares in Summit Therapeutics PLC $SMMT Acquired by Adage Capital Partners GP L.L.C.September 9, 2025 | marketbeat.comSummit Therapeutics falls -24.1%September 8, 2025 | msn.comSummit Therapeutics (SMMT) WCLC Update Call (Transcript)September 8, 2025 | seekingalpha.comSummit Therapeutics (SMMT) WCLC Update CallSeptember 8, 2025 | seekingalpha.comSummit Therapeutics shares fall as lung cancer trial results disappointSeptember 8, 2025 | proactiveinvestors.comIvonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332September 7, 2025 | prnewswire.comLonger-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in ...September 7, 2025 | finance.yahoo.comVident Advisory LLC Acquires Shares of 41,183 Summit Therapeutics PLC $SMMTSeptember 7, 2025 | marketbeat.comLonger-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLCSeptember 7, 2025 | businesswire.comCutter Capital Management LP Invests $7.72 Million in Summit Therapeutics PLC $SMMTSeptember 6, 2025 | marketbeat.comSummit Therapeutics Target of Unusually High Options Trading (NASDAQ:SMMT)September 5, 2025 | marketbeat.comSummit Therapeutics' (SMMT) Market Outperform Rating Reaffirmed at JMP SecuritiesSeptember 5, 2025 | marketbeat.comGuggenheim Initiates Coverage of Summit Therapeutics (SMMT) with Buy RecommendationSeptember 5, 2025 | msn.comSummit Therapeutics (NASDAQ:SMMT) Given Buy Rating at HC WainwrightSeptember 4, 2025 | marketbeat.comNorthern Trust Corp Has $16.27 Million Stake in Summit Therapeutics PLC $SMMTSeptember 4, 2025 | marketbeat.comSummit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025September 3, 2025 | theglobeandmail.comH.C. Wainwright Lifts PT on Summit Therapeutics (SMMT) to $50 From $44August 31, 2025 | uk.finance.yahoo.com3 No-Brainer Stocks to Buy Right NowAugust 31, 2025 | fool.comSiren L.L.C. Invests $13.41 Million in Summit Therapeutics PLC $SMMTAugust 31, 2025 | marketbeat.com Get Summit Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SMMT Media Mentions By Week SMMT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SMMT News Sentiment▼0.700.73▲Average Medical News Sentiment SMMT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SMMT Articles This Week▼169▲SMMT Articles Average Week Get the Latest News and Ratings for SMMT and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Summit Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Merck & Co., Inc. News Today Takeda Pharmaceutical News Today argenex News Today BeOne Medicines News Today Insmed News Today BioNTech News Today Teva Pharmaceutical Industries News Today Genmab A/S News Today Dr. Reddy's Laboratories News Today Ascendis Pharma A/S News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SMMT) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Summit Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SMMT Stock Alerts